Cargando…
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m(2) versus 40 mg/m(2) in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial
OBJECTIVE: The standard dose for pegylated liposomal doxorubicin (PLD) is 50 mg/m(2) every 4 weeks. While 40 mg/m(2) has recently been used in clinical practice, evidence supporting this use remains lacking. METHODS: This phase III randomized, non-inferiority study compared progression-free survival...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767649/ https://www.ncbi.nlm.nih.gov/pubmed/33185050 http://dx.doi.org/10.3802/jgo.2021.32.e9 |